ACI
NVCR icon

AMP Capital Investors’s NovoCure NVCR Stock Holding History

AMP Capital Investors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,933
Closed -$2.32M – 737
2021
Q3 		$2.32M Sell
19,933
-651
-3% -$98.4K 0.01% 703
2021
Q2 		$4.57M Buy
20,584
+3,366
+20% +$655K 0.02% 627
2021
Q1 		$2.27M Buy
17,218
+8,336
+94% +$1.32M 0.01% 748
2020
Q4 		$1.55M Buy
+8,882
New +$1.22M 0.01% 786

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AMP Capital Investors's NVCR Position: Q4 2021 in Review

AMP Capital Investors sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 19,933 shares — an estimated $2.32M sold.

AMP Capital Investors first reported a position in NVCR in Q4 2020 and held it in 4 quarters. The position peaked at $4.57M in Q2 2021. 312 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • AMP Capital Investors reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • AMP Capital Investors sold 19,933 NovoCure shares in Q4 2021, an estimated $2.32M.
  • AMP Capital Investors first reported a position in NovoCure in Q4 2020 and held it in 4 quarters.
  • AMP Capital Investors's NovoCure position peaked at $4.57M in Q2 2021.
  • 312 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on AMP Capital Investors's 13F filing for Q4 2021, filed 14 Feb 2022.